Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think a dividend also forces all shares to be accounted for? Is there a substantial amount of naked shares out?
SIGO news. Check out ASH111 post on the SIGO board.
SIGO. Check out ASH111 post on the SIGO board.
SIGO buy rating. https://www.barchart.com/stocks/quotes/SIGO/opinion
SIGO ASH111 new Lotto play. MJ stock. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133958806
I wouldn't be surprised if GSK buys it.
Wait for it.
I agree with you.
Dang it. Another one of my stocks will be down tomorrow!
BioLineRx Ltd. (NASDAQ:BLRX) PT Set at $4.00 by HC Wainwright
Posted by Samantha Guadardo on Aug 13th, 2017 // No Comments
BioLineRx Ltd. logoHC Wainwright set a $4.00 target price on BioLineRx Ltd. (NASDAQ:BLRX) in a research note issued to investors on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
https://weekherald.com/2017/08/13/biolinerx-ltd-nasdaqblrx-pt-set-at-4-00-by-hc-wainwright.html
BiondVax Receives Additional Grant Funding
PR Newswire PR NewswireAugust 14, 2017
Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development
NESS ZIONA, Israel, August 14, 2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA) announced today that the Israel Innovation Authority (IIA), formerly known as the Office of the Chief Scientist, agreed to fund upto 40% of a NIS 2.7 million (approximately US$ 750,000) budget towards ongoing development of M-001, the Company's Universal Flu Vaccine candidate.
In six previously completed human clinical trials, including the recently completed Phase 2b trial held in Europe[1], BiondVax's M-001 was shown to be safe and immunogenic towards multiple flu strains. Including today's grant approval, since 2006 the IIA has granted over US$ 6 million in funding to BiondVax. The non-dilutive grants will become repayable from royalties generated from future sales of BiondVax's vaccine, once commercially available on the market.
Dr. Tammy Ben-Yedidia, Chief Scientific Officer of BiondVax commented, "The ongoing support of our program by the IIA is proof of their long-term confidence in BiondVax's innovative flu vaccine. This grant, together with other generous recently approved financing to the company[2],[3] brings us closer to launching a Phase 3 clinical trial."
Robert Shiller and Jeremy Siegel on each other's market forecasts
BiondVax Receives Additional Grant Funding
PR Newswire PR NewswireAugust 14, 2017
Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development
NESS ZIONA, Israel, August 14, 2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA) announced today that the Israel Innovation Authority (IIA), formerly known as the Office of the Chief Scientist, agreed to fund upto 40% of a NIS 2.7 million (approximately US$ 750,000) budget towards ongoing development of M-001, the Company's Universal Flu Vaccine candidate.
In six previously completed human clinical trials, including the recently completed Phase 2b trial held in Europe[1], BiondVax's M-001 was shown to be safe and immunogenic towards multiple flu strains. Including today's grant approval, since 2006 the IIA has granted over US$ 6 million in funding to BiondVax. The non-dilutive grants will become repayable from royalties generated from future sales of BiondVax's vaccine, once commercially available on the market.
Dr. Tammy Ben-Yedidia, Chief Scientific Officer of BiondVax commented, "The ongoing support of our program by the IIA is proof of their long-term confidence in BiondVax's innovative flu vaccine. This grant, together with other generous recently approved financing to the company[2],[3] brings us closer to launching a Phase 3 clinical trial."
Ash111 I can't post on your board. Joined you on DRYS yesterday. Wish I would have a lot sooner! Looking forward to next week.
Will big pharma buy it?
OPNT news out. Still a very small market cap. Less than 50m. OPTT got a European patent that has not been news released yet.
For once my buy and hold forever has paid off.
KOL Investor Meeting, August 9th
Bellerophon will host a Key Opinion Leader lunch on the topic of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) on Wednesday, August 9 in New York City. The meeting will feature a presentation by Dr. Steven D. Nathan, who will discuss the current treatment landscape and unmet medical need for patients with PH-ILD. Dr. Nathan will be available to answer questions following the lunch.
BLPH. KOL Investor Meeting, August 9th
Bellerophon will host a Key Opinion Leader lunch on the topic of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) on Wednesday, August 9 in New York City. The meeting will feature a presentation by Dr. Steven D. Nathan, who will discuss the current treatment landscape and unmet medical need for patients with PH-ILD. Dr. Nathan will be available to answer questions following the lunch.
Bought a few OPTT today to join ASH111. I have been watching this stock for a few years now.
OPNT had moved up nicely the last few days. The CEO was on TV twice. Now my guess is since it is a very low float stock someone is going to coordinate a P&D soon. I have been long in it for at least a year. If it makes a difference Hugh jump I will be setting a stop loss. Let's see what happens over the next couple of weeks.
Not sure but it will be on my watch list.
Biondvax: European UNISEC Co-Sponsored Trial Meets Both Primary Endpoints >BVXV
OPNT is up 26%. Been moving up the last few trading sessions.
PTX is moving up.
Watch ARTH and OPTT. Both unusual activity the last few days.
Alzheimer's on 60 minutes now.
Industry Group Petitions FDA to Withdraw Approvals of Non-Abuse-Deterrent Opioids
July 7, 2017
http://www.fdanews.com/articles/182507-industry-group-petitions-fda-to-withdraw-approvals-of-non-abuse-deterrent-opioids?utm_campaign=Drug%20Daily%20Bulletin&utm_source=hs_email&utm_medium=email&utm_content=53970447&_hsenc=p2ANqtz-_ckbk2VZAOz_f4ee5PGWXiqUA2wXSetvf2rgYnNtI1MW8u4Altd3XZtLP_NTScFgcLYn_4oBnX_yT4i2KyEqA3lPTO1A&_hsmi=53970447
Anyone know if any company has been using their patents?
Wow what's going on with OPXAW?
ILNS is not even in PH 1 with something.
SYN accumulation again.
Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1
PR Newswire PR NewswireJune 13, 2017
FREMONT, Calif., June 13, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) patients have now recovered two levels of motor function and previously-announced improvements in arm, hand and finger function at 3-months and 6-months following administration of AST-OPC1 have been confirmed and further increased at 9-months.
"The new efficacy results show that previously reported meaningful improvements in arm, hand and finger function in the 10 million cell cohort treated with AST-OPC1 cells have been maintained and in some patients have been further enhanced even 9 months following dosing," stated Dr. Edward Wirth III, Chief Medical Officer. "Gains in motor function, such as the improvements observed in the SCiStar study to date, have been shown to increase a patient's ability to function independently following complete cervical spinal cord injuries. We are increasingly encouraged by these continued positive results, which are remarkable compared with spontaneous recovery rates observed in a closely matched untreated patient population."
Jane S. Lebkowski, Ph.D., Asterias' President of R&D and Chief Scientific Officer, will present the 9-month efficacy and safety data on the AIS-A 10 million cell cohort later today during the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting held in Boston, MA. The full slide presentation will be available at http://asteriasbiotherapeutics.com/inv_events_presentations.php.
9-Month Follow-up Results
PTX. SILENOR® is indicated for the treatment of insomnia characterized by dif culty with sleep maintenance.
Pernix top sponser at the Boston Sleep Conference June 3rd-7th
LINK: http://www.sleepmeeting.org/docs/default-source/attendee-documents/finalprogram_17.pdf?sfvrsn=2
Press Releases
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
Download PDF
FRAMINGHAM, MA -- (Marketwired) -- 06/06/17 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today presented a corporate update at the LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
"This has been an exciting period for Arch," said Terrence W. Norchi, President and CEO of Arch Therapeutics, Inc. "As previously announced, we expect to file for a 510(k) allowance mid-year for AC5™ designed for external use. If the 510(k) filing is allowed by the FDA, we expect that the benefit will be significant in terms of business opportunity and technology validation. We have invested significant time and effort into accelerating our plans for this regulatory application in the US, and we continue to concentrate resources on this objective. We are currently working to scale up production while evaluating and developing further indications. We expect to have commercial product available in 2018."
The 510(k) pathway enables Arch to submit a regulatory application to the FDA for external use sooner than would be possible by solely relying on the premarket approval application ("PMA") pathway. The Company still plans on taking the products being developed for internal use through the PMA process. The ability to employ the 510(k) regulatory pathway for an external use product has been an important development, and it may significantly shorten the timeframe for obtaining regulatory allowance to market a product in the US, which potentially presents a significantly greater commercial opportunity compared to Europe.
Dr. Norchi indicated that in Europe, the Company continues to work with its supply chain partners to complete the obligations required to submit an application for a CE Mark. The Company is also evaluating the impact from recent changes to the European Medical Device Regulations on the timing of a CE Mark filing and approval and, in particular, the degree to which these recent changes may affect the Company's ability to submit a CE Mark application in 2017 as previously announced. Arch anticipates providing a further update when a definitive filing date is determined and plans to file for such approval as soon as reasonable and possible.
Norchi added, "In addition, the Company has made progress on its preclinical pipeline, which includes several product applications with high unmet medical needs. These include applications for chronic cutaneous wounds, burns, surgical adhesions, gastrointestinal anastomoses and ophthalmology.
"Arch was also recently notified that the Japanese Patent Office issued a favorable trial decision to maintain in its entirety an issued patent that had been disputed and which we previously exclusively licensed from the Massachusetts Institute of Technology."
Dr. Norchi concluded, "We believe that our current cash on hand will meet our anticipated cash requirements into the third quarter of Fiscal 2018."